Home HPAPI cleaning validation considerations – Part 1
2023

HPAPI cleaning validation considerations – Part 1

by cyb2025
F. Ohsiek
Bracketing HPAPI cleaning validation HPAPI Worst-case product
Critical cleaning parameters
HPAPI CIP cleaning approach and strategy
HPAPI cleaning validation considerations
HPAPI cycle development
HPAPI recovery studies

FRED OHSIEK
Validation Manager, Ecolab Life Sciences, USA

ABSTRACT

In general, cleaning validation (CV) is a very complicated topic. The complexity is not only maneuvering within a site’s CV program, but also between industries (i.e., small molecule, biopharma, and API/finished product manufacturing). Regulatory guidelines discuss CV topics in general but not specifically to any industry. Therefore, deciphering and implementing their recommendations or expectations is often difficult.
Because high potent active pharmaceutical ingredient (HPAPI) manufacturing (API or finished product) is very high-risk from a patient safety perspective, every stage of the cleaning validation (from development to periodic monitoring) requires additional considerations and evaluation.
Every stage of the cleaning validation was assessed in respect to HPAPI manufacturing. This resulted in considerations, recommendations and solutions; which are published in this article.

INTRODUCTION
This article not only applies to the HPAPI production, but also to pharmaceutical production with HPAPIs. Therefore, the term “HPAPI manufacturing” and “HPAPI product” applies to both types of production.

 

It is important that the requirements for the finished manufacturing companies are not transferred back in the process to active pharmaceutical ingredient manufacturers without consideration for the different processes (i.e., carry-over risk) that take place at this stage (1).

 

ABOUT THE AUTHOR

Fred Ohsiek is the Sr Global Technical Manager, Life Science (Cleaning Validation) for Ecolab in North America. He earned his bachelor’s in chemistry from University of South Florida.
His professional work experience includes over 23 years of cleaning validation while working for Catalent Pharma Solutions, Amylin Pharmaceuticals, Boehringer Ingelheim, Teva Pharmaceutical Industries, Astellas Pharma Technologies Bayer (biotech division), Novo Nordisk, and Ecolab.
He has extensive risk assessment; cleaning development and validation; project start-up; legacy remediation and justification; creating/improving routine monitoring programs; and increasing manufacturing capability experience in small molecule and large molecule API and finished product manufacturing.
He was one of the authors on the new ISPE Guide: Cleaning Validation Lifecycle – Applications, Methods, and Controls and the cleaning validation acceptance criteria chapter lead.
Email Fred at Frederick.ohsiek@Ecolab.com with any questions

Latest issue

September / October 2025

View Issue

Archive

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt!

Chemistry Today - Archive
Go to archive

Content from magazine

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.
View all content

The most read

@2019 - All Right Reserved. Designed and Developed by PenciDesign

Login